Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension
Authors:
- 23 November 2011
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (sup3) , 21-29
Abstract
(2011). Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Current Medical Research and Opinion: Vol. 27, No. sup3, pp. 21-29. doi: 10.1185/03007995.2011.614936Keywords
This publication has 19 references indexed in Scilit:
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?Diabetologia, 2010
- Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controlsJournal of Diabetes Investigation, 2010
- GIP and GLP‐1, the two incretin hormones: Similarities and differencesJournal of Diabetes Investigation, 2010
- Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 DiabetesEndocrine Journal, 2010
- Is Glycemic Control Improving in U.S. Adults?Diabetes Care, 2008
- Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: replyEuropean Heart Journal, 2007
- The status of diabetes control and antidiabetic drug therapy in Japan—A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)Diabetes Research and Clinical Practice, 2006
- Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2006
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999
- U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive DiseaseDiabetes, 1995